Balyasny Asset Management LLC Affimed N.V. Transaction History

Balyasny Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.46 - $0.65 $10,808 - $15,273	-23,497 Reduced 70.05%	10,044 $4,000
Q2 2023 Aug 14, 2023	SELL	$0.57 - $1.08 $17,007 - $32,225	-29,838 Reduced 47.08%	33,541 $20,000
Q1 2023 May 15, 2023	SELL	$0.66 - $1.29 $11,553 - $22,581	-17,505 Reduced 21.64%	63,379 $47,000
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $76,222 - $169,767	69,293 Added 597.82%	80,884 $100,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $10,048 - $17,021	-5,127 Reduced 30.67%	11,591 $24,000
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $37,949 - $81,249	16,718 New	16,718 $46,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.